WALTHAM, Mass. — Scipher Medicine, a precision immunology company, has launched ClinicalTrialRank.com, an artificial intelligence (AI) platform designed to predict clinical trial failure and reshape how pharmaceutical firms and investors approach drug development.
The platform draws on more than a decade of research into the human interactome — a comprehensive protein-protein interaction map — which Scipher has used to build complex disease models. Its foundation is supported by more than 100 peer-reviewed papers.
“The development model in bio-pharma is broken as too many drugs fail in the clinic. We need to better de-risk at each stage of development. Our commercial test, PrismRA, has already proven the ability to commercially de-risk development by predicting treatment response. PrismRA is the only CMS approved treatment classifier in immunology,” said Reg Seeto, CEO of Scipher Medicine. “With ClinicalTrialRank.com, we are now impacting both pre-clinical and clinical drug development. Our proven ability to predict clinical trial failure combining network medicine, AI and proprietary data, means we enhance the overall probability of clinical development success, especially when clinical failures waste tens of billions of dollars each year. These investments could otherwise be put to better use for helping patients.”
ClinicalTrialRank.com combines genotype, phenotype, and treatment models layered onto the interactome, systematically learning from network patterns of approved drugs and patient responses. This approach ranks therapeutic targets based on their genetic relevance to disease and their ability to restore a healthy molecular profile.
Scipher has already tested the platform across 25 disease areas, where internal analysis showed that nearly all poorly ranked targets were terminated before launch. According to the company, this translates into roughly 1,000 clinical trials that could have been avoided, redirecting billions of dollars toward more promising therapies.
“From the beginning, Scipher’s mission has been to ensure patients receive the right drug, eliminating wasteful healthcare spending,” said Albert-Laszlo Barabasi, Ph.D., Scipher’s co-founder and a pioneer in network biology. “ClinicalTrialRank.com extends this mission to the earliest stages of drug discovery and development, ensuring that the drugs entering the clinic have the highest probability of success. This is not just about financial efficiency; it’s about accelerating the delivery of truly effective medicines to patients in need.”
Scipher’s leaders said the platform will serve both biopharma companies and investors by de-risking pipelines, optimizing R&D portfolios, and preventing wasted capital on drugs likely to fail.
